US46489V1044
© Globe Newswire
09.01.2026
ISR
LISTED
XASE
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
News Preview
SEATTLE, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [21...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.12.2025
ISR
LISTED
XASE
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcar...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2025
ISR
LISTED
XASE
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
News Preview
SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
20.11.2025
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming December Conferences
News Preview
SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be avail...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
10.11.2025
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
News Preview
SEATTLE, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended Septem...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2025
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming November Conferences
News Preview
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one m...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2025
ISR
LISTED
XASE
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
News Preview
SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on M...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISR
LISTED
XASE
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
News Preview
SEATTLE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first patient was treated with [212Pb]PSV359 in a second cohort of the Company’s Phase 1/2a...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
ISR
LISTED
XASE
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
News Preview
SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [2...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.09.2025
ISR
LISTED
XASE
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
News Preview
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2025
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming September Conferences
News Preview
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings wit...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2025
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results
News Preview
SEATTLE, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2025....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
24.07.2025
ISR
LISTED
XASE
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
News Preview
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation as detailed...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.07.2025
ISR
LISTED
XASE
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
News Preview
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2025 financial results and provide a business update on Wednesday, Au...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2025
ISR
LISTED
XASE
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
News Preview
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentations on its assets being delivered at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.06.2025
ISR
LISTED
XASE
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
News Preview
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.05.2025
ISR
LISTED
XASE
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
News Preview
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented at the 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
News Preview
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.04.2025
ISR
LISTED
XASE
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
News Preview
SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that data on the Company’s [212Pb]VMT-α-NET and [212Pb]VMT01 programs have been accepted for presentation a...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.04.2025
ISR
LISTED
XASE
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
News Preview
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
News Preview
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
News Preview
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ende...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.03.2025
ISR
LISTED
XASE
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
News Preview
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
ISR
LISTED
XASE
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
News Preview
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a busin...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.02.2025
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
News Preview
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.01.2025
ISR
LISTED
XASE
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.11.2024
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
News Preview
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.11.2024
ISR
LISTED
XASE
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
News Preview
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced initial results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.11.2024
ISR
LISTED
XASE
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
News Preview
SEATTLE, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsore...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
News Preview
SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.10.2024
ISR
LISTED
XASE
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
News Preview
SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company’s radiopharmaceutical programs being presented at the 37th An...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.10.2024
ISR
LISTED
XASE
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
News Preview
SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for t...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.10.2024
ISR
LISTED
XASE
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
News Preview
SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.10.2024
ISR
LISTED
XASE
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
News Preview
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2024
ISR
LISTED
XASE
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
News Preview
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
ISR
LISTED
XASE
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
News Preview
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2024
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
News Preview
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.07.2024
ISR
LISTED
XASE
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
News Preview
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 af...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2024
ISR
LISTED
XASE
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
News Preview
SEATTLE, June 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
ISR
LISTED
XASE
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
News Preview
SEATTLE, June 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates featuring the Company’s alpha-particle radiopharmaceuticals at the Society o...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.05.2024
ISR
LISTED
XASE
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
News Preview
SEATTLE, May 24, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an of...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2024
ISR
LISTED
XASE
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
News Preview
SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company’s sponsored studies of its...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
ISR
LISTED
XASE
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
News Preview
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced first quarter financial results for the period ended March 31, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.05.2024
ISR
LISTED
XASE
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
News Preview
SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming in...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.05.2024
ISR
LISTED
XASE
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
News Preview
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 befo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
